Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 4/20 | 0.76 |
| ▸ | TERT | O14746 | 4/20 | 0.57 |
| ▸ | CYCS | P99999 | 3/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2101551 | 0.98 | TOP1 (0.73) | TOP1TERTCYCSENPP2ABCG2 | |
| SCHEMBL245937 | 0.98 | TOP1 (0.78) | TOP1TERTCYCSENPP2ABCG2 | |
| SCHEMBL29961137 | 0.98 | TOP1 (0.78) | TOP1TERTCYCSENPP2ABCG2 | |
| SCHEMBL31315103 | 0.96 | TOP1 (0.76) | TOP1TERTCYCSENPP2ABCG2 | |
| SCHEMBL30915394 | 0.96 | TOP1 (0.76) | TOP1TERTCYCSENPP2ABCG2 | |
| SCHEMBL31313616 | 0.96 | TOP1 (0.76) | TOP1TERTCYCSENPP2ABCG2 | |
| SCHEMBL31313985 | 0.96 | TOP1 (0.76) | TOP1TERTCYCSENPP2ABCG2 | |
| SCHEMBL2423633 | 0.96 | TOP1 (0.76) | TOP1TERTCYCSENPP2ABCG2 | |
| Magnesium SCHEMBL31258521 | 0.96 | TOP1 (0.76) | TOP1TERTCYCSENPP2ABCG2 | |
| Hydrochloric Acid SCHEMBL2101556 | 0.96 | TOP1 (0.76) | TOP1TERTCYCSENPP2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120039987-A1 | NIOSOME HAVING METAL PORPHYRIN COMPLEX EMBEDDED THEREIN, PROCESS FOR PRODUCING THE SAME AND DRUG WITH THE USE THEREOF | MAKOTO YUASA (JP) | 2012-02-16 | — | — | US | disclosed |
| US-20080269184-A1 | Niosome Having Metal Porphyrin Complex Embedded Therein, Process For Producing The Same And Drug With The Use Thereof | YUASA, MAKOTO (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1731150-A1 | NIOSOME HAVING METAL PORPHYRIN COMPLEX EMBEDDED THEREIN, PROCESS FOR PRODUCING THE SAME AND DRUG WITH THE USE THEREOF | Yuasa, Makoto (JP) | 2006-12-13 | — | — | EP | disclosed |
| US-20050008687-A1 | Metal-porphyrin-complex-embedded liposomes, production process thereof, and medicines making use of the same | MAKOTO YUASA (JP) | 2005-01-13 | — | — | US | disclosed |
| US-6355793-B1 | ORGANOMETALLIC ZEOLITE MADE OF MULTIPLICITY OF UNITS, EACH OF WHICH IS SYMMETRICAL PORPHINE COORDINATED TO METAL ION AND SUBSTITUTED WITH AT LEAST TWO LINKING GROUPS AND OPTIONALLY WITH ONE OR MORE NON-LINKING GROUPS | ACADEMIA SINICA (TW) | 2002-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039987-A1 | NIOSOME HAVING METAL PORPHYRIN COMPLEX EMBEDDED THEREIN, PROCESS FOR PRODUCING THE SAME AND DRUG WITH THE USE THEREOF | SOD1, SOD3, GPX1 | TOP1 2966/4885TERT 2651/4885CYCS 897/4885 |
| US-20080269184-A1 | Niosome Having Metal Porphyrin Complex Embedded Therein, Process For Producing The Same And Drug With The Use Thereof | SOD1, SOD3, GPX1 | TOP1 2985/4885TERT 2642/4885CYCS 881/4885 |
| US-20050008687-A1 | Metal-porphyrin-complex-embedded liposomes, production process thereof, and medicines making use of the same | GPX4, FECH, PPOX | TOP1 3088/4885TERT 2685/4885CYCS 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.